Geopolitics Is Becoming a Regulatory Problem

How Tariffs and Geopolitics Are Changing U.S. Market Entry for International Medical Device Manufacturers

For years, regulatory strategy meant understanding the FDA.

Guidance. Pathways. Testing requirements.

That is no longer enough.

Because increasingly, market access is being shaped by geopolitics, not just regulation.

The Shift

Regulatory and global strategy used to be separate.

Now they are converging.

The U.S. medical device market alone accounts for ~40% of global demand, making it the single most important market for most manufacturers.

At the same time, global trade dynamics are shifting:

• Ongoing tariffs and trade measures continue to reshape sourcing decisions

• Governments are investing heavily in supply chain resilience for healthcare

• Manufacturers are adopting “China+1” strategies to diversify production

This is not a policy shift.

It is a competitive shift.

Supply Chains Are Now Strategic

The old assumption of stable, frictionless global supply chains is breaking down.

FDA says medical device shortages can arise from manufacturing and quality problems, public health emergencies, natural disasters, delays, discontinuations, and geopolitical issues.

During COVID, the U.S. experienced widespread shortages of critical medical devices and components, exposing how fragile global supply chains had become.

In response, governments and healthcare systems began prioritizing:

• supply continuity

• sourcing diversification

• regional reliability

The FDA has gone further by standing up an Office of Supply Chain Resilience for medical devices, with a mission centered on proactively monitoring vulnerabilities and preventing shortages.

That matters because procurement is no longer just clinical and economic.

It is becoming strategic.

This is especially true in healthcare, where shortages create immediate operational and patient-care consequences.

Regulatory Is Expanding Beyond Compliance

Regulatory has traditionally been treated as a checkpoint near the end of development.

It is becoming a lever much earlier in the process.

Each year, the FDA clears 3,000 to 3,500 devices through the 510(k) pathway, making it the primary route into the U.S. market for most manufacturers.

But access to that pathway is not evenly distributed.

Companies entering the U.S. today are not just navigating FDA requirements.

They are navigating timing windows created by:

• supply chain gaps

• shifting buyer preferences

• geopolitical positioning

Being well positioned geographically is not enough.

Without regulatory access, the opportunity is inaccessible.

A New Type of Company

A new category of manufacturer is emerging.

Not companies that build first and figure out regulation later.

Companies that design with regulatory pathways in mind from the start.

They:

• think earlier about device classification, predicate strategy, test planning, and documentation structure

• align evidence generation with target markets before the product is locked

• treat regulatory as part of go-to-market, not as a cleanup step after engineering is done

This matters because regulatory delays are expensive.

A single misstep in predicate selection or testing strategy can delay a submission by 6 to 12 months or more, sometimes requiring a full restart.

In a market where timing determines who captures demand, delay is loss: distributors, budget, momentum, and first-mover advantage.

The Real Bottleneck

There is no shortage of opportunity, manufacturing, innovation, or information in medtech regulation.

There is a shortage of execution.

The FDA publishes guidance, classification data, historical clearances, and shortage information.

The problem is not that the knowledge does not exist.

The problem is that most teams struggle to convert it into action fast enough and cleanly enough. 

The bottleneck is turning that information into:

• the right predicate strategy

• aligned testing plans

• defensible documentation

Evidence generated for one market that cannot be efficiently reused in another.

Most companies do not lose because they lack product capability.

They lose because they move too slowly through systems they do not fully understand.

What This Means

If geopolitics is shaping market access, then regulatory strategy has to move upstream.

That changes the playbook.

The manufacturers most likely to win this decade will do five things differently:

1. Pick markets earlier

   They will decide where they want to compete before product and testing plans are locked in.

2. Build evidence with multiple markets in mind

   They will design testing and documentation so the same work can support the U.S., Europe, and other target regions where possible. Many core standards, such as ISO 10993, IEC 60601, and IEC 62304, can support broader global strategies when planned correctly.

3. Treat FDA access as a commercial strategy

   Not just a regulatory milestone. A way to unlock margin, distributor relationships, and direct market entry.

4. Reduce time lost to preventable rework

   Because in a shifting market, speed matters. The company that gets in first often shapes the category.

5. Build regulatory capability before they think they need it

   Because once the market window opens, it is already too late to start from zero.

This is the deeper shift.

The question is no longer just, “Can we make this device?”

It is, “Can we turn this moment into market access before someone else does?”

Closing Thought

For years, regulatory was treated as a hurdle.

Then it became a function.

Now it is becoming infrastructure for competing in a fragmented global market.

The companies that win will not just build strong products.

They will understand how trade, supply chains, and regulation interact, and they will move earlier than everyone else.

That is the real implication of this moment.

Tariffs may be the trigger.

But the bigger story is that regulatory access is becoming one of the most important strategic assets an international manufacturer can own.